--- title: "Adipose Banking Eligibility: A Clear 2026 Explainer" description: "How adipose banking eligibility works in 2026: the screening, the donor eligibility rules, the autologous exception, and what disqualifies a sample." url: "https://savemyfat.com/adipose-banking-eligibility-qualification/" --- # How Stem Cell Bank Qualification Works: Eligibility Explained #### Table of Contents - [Oscar Tellez](https://savemyfat.com/author/oscartellez/) - September 18, 2026 - 10:00 am How stem cell bank qualification works: eligibility explained 2 Qualification in adipose banking is not one decision. It is a set of separate checks: what federal rules require of the establishment handling the tissue, which donor screening and testing provisions apply, and what a licensed provider concludes about one patient. None of them forecasts a future therapy. **TLDR Stem cell bank qualification runs on separate tracks. Federal rules at 21 CFR Part 1271 set donor screening and testing requirements, and the autologous exception at 1271.90 removes screening and testing only. Registration, listing, good tissue practice, labeling, and the 1271.10(a) criteria still apply. The rest is a provider decision. Nothing derived from adipose tissue is FDA approved for any disease, and qualifying to bank guarantees no future access or benefit.** **Important Disclaimer:** Save My Fat does not provide FDA-approved treatments or cures for any disease. Banking adipose tissue today does not guarantee eligibility, access, or clinical benefit from any future therapy, clinical trial, or medical program. No adipose-derived stem cell product currently has FDA approval for any disease. All content is for educational purposes only and does not constitute medical advice. Patients must consult their own licensed healthcare professionals regarding all medical decisions. --- People search for who qualifies for stem cell banking as though one national list exists. It does not. Qualification is doing three jobs at once. It never means a future therapy will exist, or that a person would be eligible for one. The first job is federal. FDA regulates human cells, tissues, and cellular and tissue-based products under [21 CFR Part 1271](https://www.ecfr.gov/current/title-21/chapter-I/subchapter-L/part-1271). The second belongs to the establishment handling the tissue. The third belongs to the licensed provider performing the collection. Readers new to the subject can start with [adipose tissue banking](https://savemyfat.com/what-is-adipose-tissue-banking-a-complete-guide/). ## What Qualification Means in Adipose Banking It means meeting the requirements that attach to the tissue and the establishment handling it, and nothing broader about the person. FDA’s July 2020 [guidance document](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/regulatory-considerations-human-cells-tissues-and-cellular-and-tissue-based-products-minimal) considers adipose a structural tissue, “because it is predominantly composed of adipocytes and surrounding connective tissues that provide cushioning and support to the body.” Part 1271 also sets [four criteria](https://www.ecfr.gov/current/title-21/section-1271.10) that decide whether a product falls under Section 361 alone. Anything failing them, absent an exception, is [regulated as a drug](https://www.ecfr.gov/current/title-21/section-1271.20), device, or biological product, which requires an investigational new drug application to study it. --- ## Donor Screening and Testing Under Subpart C Subpart C requires a [donor eligibility determination](https://www.ecfr.gov/current/title-21/section-1271.45) for all donors except as provided under 1271.90. That is the banking screening process in federal form. [Screening categories](https://www.ecfr.gov/current/title-21/section-1271.75) cover HIV, hepatitis B, hepatitis C, human transmissible spongiform encephalopathy including Creutzfeldt-Jakob disease, and Treponema pallidum. [Required testing](https://www.ecfr.gov/current/title-21/section-1271.85) looks for HIV type 1, HIV type 2, hepatitis B virus, hepatitis C virus, and Treponema pallidum. Viable leukocyte-rich material adds HTLV-I, HTLV-II, and CMV. Where testing applies, it must go to a [certified laboratory](https://www.ecfr.gov/current/title-21/section-1271.80) under the Clinical Laboratory Improvement Amendments of 1988, or one meeting equivalent requirements. --- ## The Autologous Exception at 1271.90 Covers Screening and Testing Only The exception is real, and narrow. The [autologous exception](https://www.ecfr.gov/current/title-21/section-1271.90) at 21 CFR 1271.90(a)(1) reads: “You are not required to make a donor-eligibility determination under 1271.50 or to perform donor screening or testing under 1271.75, 1271.80 and 1271.85 for: (1) Cells and tissues for autologous use”. Labeling does not go away. Under 1271.90(c), material stored for autologous use must be labeled “FOR AUTOLOGOUS USE ONLY,” and it must also carry “NOT EVALUATED FOR INFECTIOUS SUBSTANCES” unless the screening and testing were performed anyway. Read the scope precisely, because this is where marketing copy goes wrong. The exception covers donor screening and testing only. It is not an exception to registration, listing, current good tissue practice, labeling, or the 1271.10(a) criteria. Autologous never means that no FDA requirements apply. --- ## Does Age, Health Status, or Medical History Affect Eligibility? At the federal level, those are not what the screening rules turn on. Subpart C screening and testing are defined by the communicable disease agents listed above, and for a person’s own tissue the autologous exception removes even those requirements. Age and history matter at the provider level instead. Collection is a medical procedure, so any decision about a specific patient is clinical and made in person by a licensed clinician. Ask for the written criteria first. A product with a systemic effect, or one dependent on the metabolic activity of living cells, meets the fourth criterion at 1271.10(a) only when it is for autologous use, for allogeneic use in a first-degree or second-degree blood relative, or for reproductive use. That is where [family eligibility](https://savemyfat.com/family-eligibility-for-banked-adipose-tissue/) questions begin. --- ## Qualifying the Bank, Not Only the Patient Patients can check part of the establishment’s bar themselves. [Registration timing](https://www.ecfr.gov/current/title-21/section-1271.21) requires an establishment to register and list within 5 days after beginning operations, then update annually each December. [Listing content](https://www.ecfr.gov/current/title-21/section-1271.25) requires a statement of whether each HCT/P meets the criteria set out in 1271.10. None of that is approval, because registration and listing are self-submitted. FDA states on its [patient information page](https://www.fda.gov/vaccines-blood-biologics/consumers-biologics/important-patient-and-consumer-information-about-regenerative-medicine-therapies) that “the fact that a firm has registered with FDA and listed its product does not mean the product is legally marketed.” Registrations are searchable in FDA’s [public tissue database](https://www.accessdata.fda.gov/scripts/cber/cfappspub/tiss/index.cfm), and [how banking works](https://savemyfat.com/how-stem-cell-banking-works/) covers the full sequence. --- ## What a Laboratory Can Describe About a Sample A laboratory can describe cell surface markers and composition. It cannot certify that a stored sample will be useful for anything, and the markers used to describe one are not regulatory definitions. The IFATS and ISCT [joint statement](https://pmc.ncbi.nlm.nih.gov/articles/PMC3979435/) reports that stem and progenitor cells make up less than 0.1 percent of the stromal vascular fraction. It attaches its own caveat, that the information in that table “represents recommended guidelines only and is not to be construed as industry standards or regulatory definitions at this time.” Stromal vascular fraction is a research term here, not a service offered to anyone. FDA’s roster of [approved cellular therapies](https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/approved-cellular-and-gene-therapy-products) lists no adipose-derived product for any disease, this science remains preliminary and early stage, and only a licensed provider can advise an individual. --- ## Frequently Asked Questions ### How long does the qualification process take? No federal rule sets a timeline for one person’s intake. Part 1271 sets deadlines for establishments, not patients. Timing depends on the provider’s process and, where donor testing applies, on the laboratory running it. Ask for it in writing. ### What happens if someone does not qualify? For a person’s own tissue, 1271.90(a)(1) removes the federal donor-eligibility determination, so there is no federal pass or fail step. What remains is the provider’s clinical judgment and the establishment’s own criteria. Where screening and testing are not performed, the label must say “NOT EVALUATED FOR INFECTIOUS SUBSTANCES.” ### Does state law decide adipose tissue banking eligibility? Generally no. State statutes govern licensed professionals and consent, not whether a person may store their own tissue. Georgia’s [HB 1275](https://www.legis.ga.gov/api/legislation/document/20252026/248639), 2026 Ga. Laws Act 453, was signed in May 2026 and is effective July 1, 2026. It sets sourcing and consent rules for treating physicians and their designees, not eligibility rules for patients. No state law can approve a product or override FDA jurisdiction. ### Is banked adipose tissue FDA approved for any disease? No. FDA’s [consumer alert](https://www.fda.gov/vaccines-blood-biologics/consumers-biologics/consumer-alert-regenerative-medicine-products-including-stem-cells-and-exosomes) states that no regenerative medicine products are approved for orthopedic conditions, neurological disorders, cardiovascular or pulmonary disease, or chronic pain. Any application is preliminary and early stage. Banking does not guarantee eligibility, access, or clinical benefit later. Ask a licensed provider first. --- ## Key Takeaways Qualification in adipose banking is three questions wearing one word. Federal rules under 21 CFR Part 1271 set donor screening and testing, and the autologous exception at 1271.90 removes screening and testing only, leaving registration, listing, good tissue practice, labeling, and the 1271.10(a) criteria in force. Registration is self-submitted, not an FDA endorsement. The provider decides about the individual, so ask for written criteria and a written timeline. Published marker guidelines are not regulatory definitions. Nothing derived from adipose tissue is FDA approved for any disease, and clearing every step says nothing about any future therapy. Save My Fat operates as a tissue preservation service, not a medical practice or treatment provider. Stem cell and regenerative medicine regulations vary by state, including specific informed-consent and disclosure requirements in Florida, Utah, and Nevada governing tissue and stem cell services. Banking adipose tissue does not connect patients to any treatment pathway, and any future use depends on FDA regulatory status, physician guidance, and the availability of approved or investigational pathways at that time. Readers weighing adipose tissue banking for potential future use can review [current pricing](https://savemyfat.com/pricing/) or raise a question through the [contact page](https://savemyfat.com/contact-us/). --- *Save My Fat partners with L2 Bio for laboratory processing and storage.* *This article is for educational purposes only and does not constitute medical or legal advice. Legal and medical review including neurology and neurosurgery input is required before publication. Please consult your neurologist or neurosurgeon before making any decisions about adipose tissue banking or research participation.* **About the author:** Oscar Tellez is the founder and CEO of Save My Fat. He holds a Bachelor of Science in Exercise Science and Health Promotion from Florida Atlantic University. He has spent more than a decade in the regenerative medicine industry across product distribution, laboratory and vendor relationships, and provider training. He is not a licensed clinician, and this article is educational, not medical advice. **Related guide:** [FDA adipose tissue regulation](https://savemyfat.com/fda-regulation-adipose-tissue/). Follow Save My Fat on Google Set us as a preferred source and Google will show our latest updates more often in your results. [PrevPreviousAdipose, Bone Marrow, and Cord: Why the Tissue Source Matters](https://savemyfat.com/stem-cells-tissue-source-comparison/) [NextExosome Banking: How It Differs From Whole-Cell Adipose BankingNext](https://savemyfat.com/exosome-banking-vs-adipose-banking/) Exosomes ### [Exosome Banking: How It Differs From Whole-Cell Adipose Banking](https://savemyfat.com/exosome-banking-vs-adipose-banking/) [Read More »](https://savemyfat.com/exosome-banking-vs-adipose-banking/) Oscar Tellez 09/19/2026 10:00 AM [![Microscope and monitor showing magnified cells beside a petri dish under blue light, the screening behind adipose banking](https://savemyfat.com/wp-content/uploads/2026/08/adipose-banking-eligibility-qualification-768x768.png)](https://savemyfat.com/adipose-banking-eligibility-qualification/) Adipose Banking ### [How Stem Cell Bank Qualification Works: Eligibility Explained](https://savemyfat.com/adipose-banking-eligibility-qualification/) [Read More »](https://savemyfat.com/adipose-banking-eligibility-qualification/) Oscar Tellez 09/18/2026 10:00 AM [![Lab instrument and monitor showing magnified cells beside glowing sample tubes, where stem cells are characterized](https://savemyfat.com/wp-content/uploads/2026/08/stem-cells-tissue-source-comparison-768x768.png)](https://savemyfat.com/stem-cells-tissue-source-comparison/) Stem Cells ### [Adipose, Bone Marrow, and Cord: Why the Tissue Source Matters](https://savemyfat.com/stem-cells-tissue-source-comparison/) [Read More »](https://savemyfat.com/stem-cells-tissue-source-comparison/) Oscar Tellez 09/17/2026 10:00 AM Adipose ### [Adipose-Derived Stem Cell Market Size and Growth Trends for Patients](https://savemyfat.com/adipose-stem-cell-market-size-2026/) [Read More »](https://savemyfat.com/adipose-stem-cell-market-size-2026/) Oscar Tellez 09/16/2026 10:00 AM Regulation ### [Are Stem Cells Legal in the US? Answering the Most Common Question](https://savemyfat.com/are-stem-cells-legal-in-the-us/) [Read More »](https://savemyfat.com/are-stem-cells-legal-in-the-us/) Oscar Tellez 09/15/2026 10:00 AM Regulation ### [Is Stem Cell Therapy Legal in the US? A State-by-State Answer](https://savemyfat.com/is-stem-cell-therapy-legal-us/) [Read More »](https://savemyfat.com/is-stem-cell-therapy-legal-us/) Oscar Tellez 09/14/2026 10:00 AM ```json [{"@context":"https:\/\/schema.org","@graph":[{"@type":"BreadcrumbList","@id":"https:\/\/savemyfat.com\/adipose-banking-eligibility-qualification\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":"1","item":{"@id":"https:\/\/savemyfat.com","name":"Home"}},{"@type":"ListItem","position":"2","item":{"@id":"https:\/\/savemyfat.com\/our-blog\/","name":"Our Blog"}},{"@type":"ListItem","position":"3","item":{"@id":"https:\/\/savemyfat.com\/category\/adipose-banking\/","name":"Adipose Banking"}},{"@type":"ListItem","position":"4","item":{"@id":"https:\/\/savemyfat.com\/adipose-banking-eligibility-qualification\/","name":"How Stem Cell Bank Qualification Works: Eligibility Explained"}}]}]},{"@context":"https:\/\/schema.org","@graph":[{"@type":"Person","@id":"https:\/\/savemyfat.com\/oscar-tellez\/#person","name":"Oscar Tellez","jobTitle":"Founder","description":"Oscar Tellez is the Founder of SaveMyFat, a company that connects patients and physicians with a U.S. tissue bank for adipose tissue banking, so a person's own tissue can be preserved for potential future use in FDA-regulated pathways. He is not a physician.","url":"https:\/\/savemyfat.com\/oscar-tellez","email":"info@savemyfat.com","image":{"@type":"ImageObject","url":"https:\/\/savemyfat.com\/wp-content\/uploads\/2026\/05\/Oscar-Headshot-Rounded-1.png","width":"200","height":"200"},"worksFor":{"@type":"Organization","@id":"https:\/\/savemyfat.com\/#organization","name":"SaveMyFat","url":"https:\/\/savemyfat.com"},"knowsAbout":["Adipose Tissue Banking","Cryopreservation","Regenerative Medicine Regulation","Adipose-Derived Cells","Expanded Access Pathways"],"sameAs":["https:\/\/savemyfat.com\/oscar-tellez","https:\/\/www.linkedin.com\/in\/o-tellez\/","https:\/\/www.facebook.com\/savemyfat\/","https:\/\/www.instagram.com\/savemyfat\/"]},{"@type":"Article","@id":"https:\/\/savemyfat.com\/adipose-banking-eligibility-qualification\/#article","headline":"How Stem Cell Bank Qualification Works: Eligibility Explained","url":"https:\/\/savemyfat.com\/adipose-banking-eligibility-qualification\/","mainEntityOfPage":{"@type":"WebPage","@id":"https:\/\/savemyfat.com\/adipose-banking-eligibility-qualification\/"},"datePublished":"2026-09-18T10:00:00-04:00","dateModified":"2026-08-26T17:28:46-04:00","description":"How adipose banking eligibility works in 2026: the screening, the donor eligibility rules, the autologous exception, and what disqualifies a sample.","inLanguage":"en-US","articleSection":"Adipose Tissue Banking","author":{"@type":"Person","@id":"https:\/\/savemyfat.com\/oscar-tellez\/#person","name":"Oscar Tellez","jobTitle":"Founder","url":"https:\/\/savemyfat.com\/oscar-tellez"},"publisher":{"@type":"Organization","@id":"https:\/\/savemyfat.com\/#organization","name":"SaveMyFat","url":"https:\/\/savemyfat.com"},"image":"https:\/\/savemyfat.com\/wp-content\/uploads\/2026\/08\/adipose-banking-eligibility-qualification.png"}]},{"@context":"https:\/\/schema.org","@type":"WebPage","@id":"https:\/\/savemyfat.com\/adipose-banking-eligibility-qualification\/#webpage","url":"https:\/\/savemyfat.com\/adipose-banking-eligibility-qualification\/","name":"Adipose Banking Eligibility: A Clear 2026 Explainer","speakable":{"@type":"SpeakableSpecification","cssSelector":[".smf-speakable"]}}] ```